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Results: Gemfibrozil unexpectedly reduced the peak plasma con-
centration (Cmax) of imatinib by 35% (P < 0.001). Gemfibrozil also 
reduced the Cmax and area under the plasma concentration–time curve 
(AUC0–∞) of N-DMI by 56% and 48% (P < 0.001), while the AUC0–∞ 
of imatinib was unaffected. Furthermore, gemfibrozil reduced the 
Cmax/C24 h ratios of imatinib and N-DMI by 44% and 17% (P < 
0.05), suggesting diminished daily fluctuation of imatinib plasma 
concentrations during concomitant use with gemfibrozil. PBPK simu-
lations suggested an increased contribution (70%) for CYP2C8 to the 
hepatic metabolic clearance of imatinib during long-term treatment 
with the most common imatinib dosing, 400 mg once daily. The 
impaired imatinib absorption observed during the gemfibrozil phase 
was best explained by inhibition of an intestinal influx transporter 
involved in imatinib absorption.
Conclusion: This study shows for the first time that CYP2C8 is 
important in the metabolism of imatinib in humans, and that an 
influx transporter may be relevant for imatinib absorption in vivo. 
Given that the efficacy and adverse effects of imatinib are dose-
dependent, care is warranted when gemfibrozil is used in combina-
tion with imatinib.
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Introduction: There are still controversies over pill substitution 
among AEDs: some studies claimed that switching between brand 
and generic AED (generic substitution) can lead to breakthrough 
seizures; other studies have refuted these concerns. France and some 
US states recommend limiting substitution of generic AED. We aimed 
at further estimating the association between generic substitution and 
loss of seizure control.
Patients (or Materials) and Methods: We used data from the French 
National Health Insurance Information System linked with the 
French Hospital Discharge Database to identify a cohort of patients 
aged 18 years or more who filled a prescription in 2010 for AED 
that had at least 1 brand-name and 1 generic form available on the 
French market (carbamazepine, lamotrigine, levetiracetam, oxcar-
bazepine, topiramate, or valproic acid). Patients with a medical his-
tory of stroke or cancer and women who gave birth (ICD-10 codes, 
O80–O84) were excluded. We used a case-crossover design to assess 
the relationship between seizure-related hospitalization and generic 
substitution. For this preliminary analysis, cases were identified as 
individuals with a seizure-related hospitalization between July 2010 
and December 2010 (ICD-10 codes, G40 or G41). The index date 
was defined as the date of first occurrence in the inpatient file of the 
codes of interest pending a preceding hospitalization-free period of at 
least 6 months with regular dispensations of targeted AED. The case 
period corresponded to the 3 months preceding the index date; the 
control period was defined as the 3 months immediately preceding the 
case period. Generic substitution was defined as a filled prescription 
for a generic AED that was preceded by a filled prescription for a 
brand-name counterpart. Matched odds ratio estimates were based 
on the ratio of discordant pairs of case and control periods in regard 
to generic substitution; ORs and 95% CIs were estimated using con-
ditional logistic regression model. All analyses were conducted using 
the SAS statistical package (version 9.2; SAS Institute).
Results: The cohort included 566,549 adult patients filling targeted 
AED. We identified 10,089 patients with eligible seizure-related hos-
pitalization in the second half of 2010, excluding stroke, cancer, and 
childbirth. Among them, 2980 had regular dispensations. Generic 
substitution was observed in 461 patients, 273 in the case period and 
258 in the control period; matched OR = 1.08 (95% CI, 0.88–1.32).
Conclusion: Generic substitution was not associated with an elevated 
risk of seizure-related hospitalization.
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Introduction: Studies have shown that the cloned enzyme donor 
immunoassays (CEDIA) for buprenorphine, methadone, and 2-eth-
ylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) might be suit-
able for drugs-of-abuse testing in urine, but sensitivity, specificity, 
and optimal cutoff are to be determined. The aim of this study was 
to evaluate the overall performance of CEDIA compared with liquid 
chromatography tandem mass spectrometry (LC-MS/MS) for analy-
sis of buprenorphine, methadone, and EDDP in urine.
Patients (or Materials) and Methods: All urine samples sent to the 
Laboratory of Clinical Biochemistry at the Haukeland University 
Hospital for drugs-of-abuse testing in a period of 4 weeks in 
November–December 2011 were consecutively analyzed with both 
CEDIA and LCMSMS. Samples were from heroin-addicted patients 
enrolled in medication-assisted rehabilitation (MAR), treated with 
either buprenorphine or methadone, and from patients who were not 
treated with these drugs (non-MAR).
Results: A total of 2272 urine samples were included in the study; 
996 urine samples (43% of all samples) were from patients enrolled 
in MAR. The CEDIA assay for methadone, EDDP, and buprenorphine 
had a sensitivity of 97.4%, 98.8%, and 100% and a specificity of 
100%, 100%, and 98.0%, respectively. All samples with false-negative 
results in the CEDIA EDDP assay had also false-negative results in the 
methadone assay. A change in the CEDIA buprenorphine assay cutoff 
from the manufacturer’s recommendation on 5 ng/mL to 10 ng/mL 
gave a better specificity, with a reduction from 32 to 5 false-positive 
results. Most of the false-positive results in the CEDIA buprenorphine 
assay could be explained by cross-reactivity with codeine and mor-
phine but in concentrations lower than previously reported.
Conclusion: The CEDIA assays for buprenorphine and EDDP are 
suitable as screening methods for drugs-of-abuse testing in urine. The 
methadone assay did not provide additional information to the EDDP 
assay and may be redundant. We propose a cutoff concentration 
of 10 ng/mL for the CEDIA buprenorphine assay. Cross-reactivity 
